Fig. 34

⁶⁸Ga-PSMA, prostate cancer, biochemical recurrence (BCR): 223Ra feasability. Clinical history: 72 y.o. man with prostate cancer, radical prostatectomy as primary treatment Gleason score 4 + 3; during abiraterone treatment, PSA increased up to 127 ng/ml, candidate to 223Ra chloride. PET/CT findings: multiple foci of increased uptake in the bones. No lymph node or visceral metastases. After ⁶⁸Ga-PSMA PET/CT, the patient has been referred to 223Ra chloride treatment. a MIP; b fused images